SARCOMA: UNCLASSIFIED

 

Regimen/Number

Of Patients

Drug Dose and Route

Leukopenia/

Neutropenia

Toxicity

Anemia

Toxicity

Other

Grade III-IV Toxicities

Emetogenic

Potential

Consequences of

Adverse Event(s)

AD

(Antman K, et al.

J Clin Oncol.

1993;11:1276-85)

 

N = 170

Doxorubicin 15 mg/m2/d continuous

infusion days 1-4

Dacarbazine 250 mg/m2/d IV continuous

infusion days 1-4

Repeat cycle every 21 days

Neutropenia

Grade III-IV

38%

Leukopenia

Grade III-IV

32%

Grade III-IV

6.5 %

Nausea/ Vomiting 9 %

Thrombocytopenia  4%

Cardiac 1 %

Mucositis/ Stomatitis 7%

Diarrhea < 1 %

 

Days 1 – 4 –

Level 5

1 death due to

pulmonary embolism

 

DI

(Schutte J, et al.

Eur J Cancer.

1990;26:558-61)

 

N = 175

Doxorubicin 50 mg/m2 IV bolus, day 1

Ifosfamide 5000 mg/m2/d IV continuous

Infusion followed doxorubicin, day 1

Mesna 600 mg/m2 IV bolus before

ifosfamide, 2500 mg/m2/d IV continuous

infusion with ifosfamide, 1250 mg/m2 IV

over 12 hours following ifosfamide

Repeat cycle every 21 days

Leukopenia

Grade III-IV

73%

Grade IV 34%

 

Neutropenic Fever 2%

Documented infection 6%

Fever 2 %

Thrombocytopenia * 5%

Nausea/Vomiting 41%

Alopecia 71%

Diarrhea 2%

Oral 3%

Renal 2 %

Cardiac 1 %

Consciousness 3%

Hematuria 2 %

* < 75.000 /mm3

Day 1 –

Level 4

Toxic death 1 %

Modify treatment

(of courses) 26%

Discontinue

teatment 11 %

Doxoribicin

(Nielsen OS, et al.

BR J Cancer.

1998;78:1634-39)

 

N = 104

Doxorubicin 75 mg/m2 IV day 1

Repeat cycle every 21 days

Neutropenia

Grade III 30%

Grade IV 21%

Leukopenia

Grade III 30%

Grade IV 8%

 

Infection 3%

Nausea/Vomiting 13 %

Thrombocytopenia 2 %

Mucositis 6 %

Cardiotoxicity 1 %

 

Day 1 –

Level 4

Dose intensity 97 %

1 patient death due

to cardiotoxicity

 

IE

(Edmonson JH, et al.

J Natl Cancer Inst.

1989;89:863-66)

 

N = 44

Mesna at 20% of ifosfamide dose

prior to ifosfamide, at completion of

etoposide infusion, and then every

4 hours for a further 3 doses

Ifosfamide 2500 mg/m2/d IV days 1-3,

followed by

Etoposide 100 mg/m2/d IV days 1-3

Repeat cycle every 28 days

Leukopenia

Grade IV 38%

 

Neutropenic Fever

During Leukopenia 5 %

Nausea/Vomiting * 70 %

Thrombocytopenia 3 %

Alopecia (significant)* 85%

Renal Failure* 2 %

 

* Grade unknown

Days 1 – 3 –

Level 4

No toxic mortality